menu
    • menu

    Company profile for Nacuity Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nacuity Pharmaceuticals, Inc. is a clinical stage pharmaceutical company whose mission is to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Our lead technology is based on studies from the laboratory of Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina. Nacuity has assembled an accomplished team and has received ...
    Nacuity Pharmaceuticals, Inc. is a clinical stage pharmaceutical company whose mission is to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Our lead technology is based on studies from the laboratory of Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina. Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nacuity PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    306 W. 7th St, Ste. 310 Fort Worth, TX 76102
    Telephone
    Telephone
    +1-817-336-3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nacuity.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nacuity Pharma Receives FDA Breakthrough Status For NPI-001
    Nacuity Pharma Receives FDA Breakthrough Status For NPI-001

    02 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160415/0/en/Nacuity-Pharmaceuticals-Granted-U-S-FDA-Breakthrough-Therapy-Designation-for-NPI-001-N-acetylcysteine-amide-Tablets-for-the-Treatment-of-Retinitis-Pigmentosa.html

    GLOBENEWSWIRE
    02 Oct 2025
    Share Share
    Nacuity Pharma Reports Positive NPI-001 Trial for Usher Syndrome
    Nacuity Pharma Reports Positive NPI-001 Trial for Usher Syndrome

    11 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/11/3148593/0/en/Nacuity-Pharmaceuticals-Announces-Positive-Data-from-Clinical-Trial-Evaluating-NPI-001-to-Treat-Retinitis-Pigmentosa-Associated-with-Usher-Syndrome.html

    GLOBENEWSWIRE
    11 Sep 2025
    Share Share
    Nacuity Gets FDA Fast Track For Retinitis Pigmentosa Drug NPI-001
    Nacuity Gets FDA Fast Track For Retinitis Pigmentosa Drug NPI-001

    21 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/21/3012724/0/en/Nacuity-Pharmaceuticals-Granted-U-S-FDA-Fast-Track-Designation-for-NPI-001-N-acetylcysteine-amide-Tablets-for-the-Treatment-of-Retinitis-Pigmentosa.html

    GLOBENEWSWIRE
    21 Jan 2025
    Share Share
    Nacuity: First Patients In Final Cohort Of NPI-002 Cataract Trial
    Nacuity: First Patients In Final Cohort Of NPI-002 Cataract Trial

    30 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/30/2872335/0/en/Nacuity-Pharmaceuticals-Announces-First-Patients-Implanted-in-Final-Cohort-of-Phase-1-2-Clinical-Trial-Evaluating-NPI-002-Intravitreal-Implant-for-the-Delay-of-Cataract-Progression.html

    GLOBENEWSWIRE
    30 Apr 2024
    Share Share
    Nacuity Pharma Appoints Dr. Emmett Cunningham, Jr. to Board of Directors
    Nacuity Pharma Appoints Dr. Emmett Cunningham, Jr. to Board of Directors

    16 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/16/2863683/0/en/Nacuity-Pharmaceuticals-Expands-Board-of-Directors-with-Appointment-of-Dr-Emmett-Cunningham-Jr.html

    GLOBENEWSWIRE
    16 Apr 2024
    Share Share
    Arctic and Nacuity Announce EMA Approval to Initiate First Trial of AT-001
    Arctic and Nacuity Announce EMA Approval to Initiate First Trial of AT-001

    12 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/12/2844590/0/en/Arctic-Therapeutics-and-Nacuity-Pharmaceuticals-Announce-European-Medicines-Agency-Approval-to-Initiate-First-Clinical-Trial-of-AT-001-NPI-001-for-the-Treatment-of-HCCAA.html

    GLOBENEWSWIRE
    12 Mar 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search